Jose Soto Soto, MD
Pulmonary Disease · Jacksonville, FLNPI 1275797177
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $413,425 of the $504,476 with a category attached, or 82.0%. GSK accounts for 75.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $153,946 and has fallen 90.8% since, to $14,205 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $1159.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$381K
- Genentech USA, Inc.$88K
- Sanofi$14K
- Boehringer Ingelheim$12K
- Regeneron Healthcare Solutions, Inc.$4K
- Intuitive Surgical$4K
- plus $3K from 21 others
Across 2 payments — averaging $22,402 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$37K
- Boehringer Ingelheim$8K
What the payments were for
- Consulting fees$26,1765%
- Speaking & faculty fees$413,42582%
- Travel & lodging$51,19610%
- Food & beverage$10,0612%
- Education$3,6171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 238 | $380,614 |
| Genentech USA, Inc. | 93 | $88,130 |
| Sanofi | 9 | $13,663 |
| Boehringer Ingelheim | 28 | $11,708 |
| Regeneron Healthcare Solutions, Inc. | 9 | $4,040 |
| Intuitive Surgical | 6 | $3,732 |
| Mallinckrodt Enterprises LLC | 4 | $468 |
| AstraZeneca | 10 | $421 |
| United Therapeutics Corporation | 6 | $386 |
| Actelion Pharmaceuticals US, Inc. | 5 | $279 |
| Insmed, Inc. | 3 | $163 |
| E.r. Squibb & Sons, L.L.C. | 2 | $130 |
| Inspire Medical Systems, Inc. | 1 | $128 |
| Verona Pharma, Inc. | 1 | $125 |
| Pulmonx Corporation | 1 | $97 |
| Boston Scientific | 1 | $59 |
| Mylan Specialty L.p. | 2 | $49 |
| Genentech, Inc. | 1 | $47 |
| Gilead | 2 | $43 |
| Philips North America LLC | 3 | $40 |
| AbbVie | 2 | $29 |
| Pfizer | 2 | $28 |
| Novartis | 2 | $27 |
| Shire North American Group Inc | 1 | $22 |
| Grifols USA, LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$504,476 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $157,191 |
| Dupixent PenDupilumab | 13 | $50,232 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $39,756 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,940 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $12,640 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $8,851 |
| Spiriva RespimatTiotropium Bromide | 15 | $8,783 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,513 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,421 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $2,272 |
| Montelukast Sodium | 50 | $499 |
| Fluticasone Propionate | 31 | $411 |
| Omeprazole | 24 | $282 |
| Gabapentin | 24 | $271 |
| Prednisone | 30 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $380,614 | $52,39580 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $421 | $21,87443 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $11,708 | $17,63528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville
- Jennifer FultonJacksonville$665K
- Jorge MalleaJacksonville$457K
- Abubakr BajwaJacksonville$414K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Charles BurgerJacksonville$124K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
- Franck RahaghiWeston$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.